These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37969188)

  • 21. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
    Ghaffari SH; Bashash D; Dizaji MZ; Ghavamzadeh A; Alimoghaddam K
    Tumour Biol; 2012 Feb; 33(1):157-72. PubMed ID: 22072212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Hassani S; Khaleghian A; Ahmadian S; Alizadeh S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Ann Hematol; 2018 Jan; 97(1):83-93. PubMed ID: 29159499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC; Dang CV
    Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
    Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
    Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
    Jo S; Lee YL; Kim S; Lee H; Chung H
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
    [No Abstract]   [Full Text] [Related]  

  • 27. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
    Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
    Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
    Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptomic analysis of the PI3K/Akt signaling pathway reveals the dual role of the c-Jun oncogene in cytotoxicity and the development of resistance in HL-60 leukemia cells in response to arsenic trioxide.
    Roszak J; Smok-Pieniążek A; Stępnik M
    Adv Clin Exp Med; 2017 Dec; 26(9):1335-1342. PubMed ID: 29442453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of key candidate genes and biological pathways in bladder cancer.
    Gao X; Chen Y; Chen M; Wang S; Wen X; Zhang S
    PeerJ; 2018; 6():e6036. PubMed ID: 30533316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology.
    Dawood M; Hamdoun S; Efferth T
    Front Pharmacol; 2018; 9():143. PubMed ID: 29535630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic compounds: The wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology.
    Liu G; Song Y; Li C; Liu R; Chen Y; Yu L; Huang Q; Zhu D; Lu C; Yu X; Xiao C; Liu Y
    Eur J Med Chem; 2021 Oct; 221():113519. PubMed ID: 33984805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
    Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
    Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
    Nitto T; Sawaki K
    J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin.
    Hu X; Li H; Ip TK; Cheung YF; Koohi-Moghadam M; Wang H; Yang X; Tritton DN; Wang Y; Wang Y; Wang R; Ng KM; Naranmandura H; Tse EW; Sun H
    Chem Sci; 2021 Aug; 12(32):10893-10900. PubMed ID: 34476069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.
    Liu Q; Zhang H; Smeester L; Zou F; Kesic M; Jaspers I; Pi J; Fry RC
    BMC Med Genomics; 2010 Aug; 3():37. PubMed ID: 20707922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
    Gao C; Lin L; Li J; Wu M; Lv J; Tian S; Hai X
    Toxicol Lett; 2023 May; 380():31-39. PubMed ID: 37024065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acute promyelocytic leukemia: state-of-the-art management].
    Asou N
    Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay of Ubiquitin-Like Modifiers Following Arsenic Trioxide Treatment.
    Rinfret Robert C; McManus FP; Lamoliatte F; Thibault P
    J Proteome Res; 2020 May; 19(5):1999-2010. PubMed ID: 32223133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.